A randomized, multicenter, phase II trial of camrelizumab (Cam) with and without metastasis-directed therapy (MDT) in recurrent/metastatic nasopharyngeal carcinoma (R/M-NPC).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Xin Zhang, Jin Yan, Qianqian Lei, Lu Zhang, Jieying Yang, Sze Huey Tan, Melvin L.K. Chua, Ying Wang, Jiangdong Sui
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401516315